Elevated IL-1 levels have been found in BD since 1990 and have been confirmed in subsequent studies, laying a theoretical foundation for the use of an IL-1 antagonist as a therapeutic agent in BD [123,124]. This evidence concerns the gene IL1B and Behcet disease.